Anti-Thyroglobulin Antibodies as a Surrogate Tumor Marker for the Follow-Up of the Differentiated Thyroid Carcinoma: Clinical Implications and Pitfalls

Balkan Medical Journal 2026 Open access

Read full text
Authors: Esra Eraslan Aydemir, Feride Özkara Akkuş, Murat Faik Erdoğan
DOI: 10.4274/balkanmedj.galenos.2026.2026-3-145
Cited by: 1
References: 25

Abstract

antithyroglobulin antibody positivity does not appear to serve as an early biomarker of recurrence. In antithyroglobulin antibody-positive patients, imaging-based surveillance, particularly neck ultrasonography, remains the cornerstone of follow-up. In conclusion, TgAb act as both interferents and surrogate tumor markers in DTC surveillance, and the integrated use of antithyroglobulin antibody trends and imaging is necessary for the optimal management of antithyroglobulin antibody-positive patients.

Fields of Study & Subjects

Thyroid Cancer Diagnosis and Treatment Neuroendocrine Tumor Research Advances Thyroid Disorders and Treatments

Publication details

Journal / source
Balkan Medical Journal
Publisher
Galenos Yayinevi
Volume
43
Issue
5
Pages
230–237
Publication date
30 April 2026
Language
EN